Trials / Completed
CompletedNCT06499298
Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer
Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer: A Non-interventional Study in China
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 64 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the real-world effectiveness and patterns of use of adjuvant nivolumab in adult participants with Stage II/III Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC) in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | As per product label, as prescribed by treating physician |
Timeline
- Start date
- 2024-12-03
- Primary completion
- 2025-04-16
- Completion
- 2025-04-16
- First posted
- 2024-07-12
- Last updated
- 2025-05-31
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06499298. Inclusion in this directory is not an endorsement.